Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARCTNASDAQ:BMRANASDAQ:TRDANASDAQ:TSHA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARCTArcturus Therapeutics$12.91+0.2%$12.86$8.04▼$45.00$350.12M3.41455,183 shs279,416 shsBMRABiomerica$3.88+3.2%$4.97$1.93▼$10.16$9.88M0.37280,246 shs31,977 shsTRDAEntrada Therapeutics$8.84-1.3%$9.94$7.10▼$21.79$332.34M0.04125,486 shs96,288 shsTSHATaysha Gene Therapies$1.76-3.3%$1.55$1.05▼$4.32$360.90M0.962.70 million shs1.70 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARCTArcturus Therapeutics+1.90%+22.41%+0.94%-24.71%-52.22%BMRABiomerica+2.73%-2.08%-30.06%-21.80%-34.08%TRDAEntrada Therapeutics+2.87%+10.21%-11.98%-30.22%-27.92%TSHATaysha Gene Therapies0.00%+46.77%+2.82%+19.74%-22.55%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARCTArcturus Therapeutics3.1188 of 5 stars4.60.00.00.03.82.50.6BMRABiomerica0.4155 of 5 stars0.03.00.00.02.20.80.0TRDAEntrada Therapeutics2.1029 of 5 stars3.62.00.00.00.61.71.3TSHATaysha Gene Therapies3.1041 of 5 stars3.53.00.00.03.51.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARCTArcturus Therapeutics 3.13Buy$59.20358.56% UpsideBMRABiomerica 0.00N/AN/AN/ATRDAEntrada Therapeutics 3.25Buy$25.67190.35% UpsideTSHATaysha Gene Therapies 3.00Buy$6.63276.42% UpsideCurrent Analyst Ratings BreakdownLatest BMRA, TRDA, ARCT, and TSHA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/10/2025ARCTArcturus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.00 ➝ $60.004/10/2025TSHATaysha Gene TherapiesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.003/31/2025TRDAEntrada TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.003/10/2025ARCTArcturus TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$48.003/10/2025ARCTArcturus TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$74.00 ➝ $68.003/7/2025ARCTArcturus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$63.00 ➝ $60.003/7/2025ARCTArcturus TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight3/7/2025ARCTArcturus TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$58.00 ➝ $50.002/27/2025TSHATaysha Gene TherapiesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.002/26/2025TSHATaysha Gene TherapiesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.002/25/2025TRDAEntrada TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.00(Data available from 4/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARCTArcturus Therapeutics$138.39M2.53N/AN/A$10.42 per share1.24BMRABiomerica$5.68M1.74N/AN/A$0.39 per share9.95TRDAEntrada Therapeutics$210.78M1.58N/AN/A$7.26 per share1.22TSHATaysha Gene Therapies$8.33M43.31N/AN/A$0.40 per share4.40Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARCTArcturus Therapeutics-$29.73M-$3.01N/AN/AN/A-36.39%-22.39%-14.81%5/12/2025 (Estimated)BMRABiomerica-$5.98M-$2.32N/A∞N/A-100.52%-90.19%-64.54%N/ATRDAEntrada Therapeutics-$6.68M$1.915.56N/AN/A25.53%16.11%10.39%5/6/2025 (Estimated)TSHATaysha Gene Therapies-$111.57M-$0.362.79N/AN/A-229.67%-106.36%-49.16%5/13/2025 (Estimated)Latest BMRA, TRDA, ARCT, and TSHA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025TSHATaysha Gene Therapies-$0.08N/AN/AN/A$1.48 millionN/A5/12/2025Q1 2025ARCTArcturus Therapeutics-$1.10N/AN/AN/A$25.64 millionN/A5/6/2025Q1 2025TRDAEntrada Therapeutics-$0.78N/AN/AN/A$10.98 millionN/A4/14/2025Q3 2025BMRABiomericaN/A-$0.48N/A-$0.06N/A$1.12 million3/6/2025Q4 2024ARCTArcturus Therapeutics-$0.33-$1.11-$0.78-$1.11$44.64 million$22.77 million2/27/2025Q4 2024TRDAEntrada Therapeutics-$0.66$0.03+$0.69$0.03$11.95 million$12.25 million2/26/2025Q4 2024TSHATaysha Gene Therapies-$0.08-$0.07+$0.01-$0.07$2.05 million$2.02 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARCTArcturus Therapeutics$0.715.54%N/AN/A N/ABMRABiomericaN/AN/AN/AN/AN/ATRDAEntrada TherapeuticsN/AN/AN/AN/AN/ATSHATaysha Gene TherapiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARCTArcturus TherapeuticsN/A4.764.76BMRABiomericaN/A3.172.22TRDAEntrada TherapeuticsN/A6.596.59TSHATaysha Gene Therapies0.485.515.51Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARCTArcturus Therapeutics94.54%BMRABiomerica22.28%TRDAEntrada Therapeutics86.39%TSHATaysha Gene Therapies77.70%Insider OwnershipCompanyInsider OwnershipARCTArcturus Therapeutics15.30%BMRABiomerica15.00%TRDAEntrada Therapeutics7.59%TSHATaysha Gene Therapies2.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARCTArcturus Therapeutics18027.12 million22.94 millionOptionableBMRABiomerica602.55 million15.59 millionOptionableTRDAEntrada Therapeutics11037.60 million34.58 millionOptionableTSHATaysha Gene Therapies180205.06 million199.41 millionOptionableBMRA, TRDA, ARCT, and TSHA HeadlinesRecent News About These CompaniesAvoro Capital Advisors LLC Buys 1,349,999 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA)April 23 at 7:22 AM | marketbeat.comB Group Inc. Buys Shares of 965,556 Taysha Gene Therapies, Inc. (NASDAQ:TSHA)April 23 at 6:54 AM | marketbeat.comWhy Taysha Gene Therapies, Inc.’s (TSHA) Stock Is Up 16.13%April 22 at 11:48 AM | aaii.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Shares Sold by JPMorgan Chase & Co.April 21, 2025 | marketbeat.comVanguard Group Inc. Raises Stock Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)April 20, 2025 | marketbeat.comTaysha Gene Therapies: Sell Rating On Uncertain Pipeline Prospects And Limited OpportunityApril 16, 2025 | seekingalpha.comNorges Bank Takes $2.53 Million Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)April 14, 2025 | marketbeat.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Average Rating of "Buy" by AnalystsApril 7, 2025 | marketbeat.comWells Fargo Reaffirms Their Buy Rating on Taysha Gene Therapies (TSHA)April 5, 2025 | markets.businessinsider.comTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)April 4, 2025 | globenewswire.comWhy Taysha Gene Therapies, Inc.’s (TSHA) Stock Is Down 11.15%April 1, 2025 | aaii.comIs Taysha Gene Therapies (TSHA) the Best Short Squeeze Stock to Buy According to Analysts?March 19, 2025 | msn.comTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)March 7, 2025 | globenewswire.comTruist Financial Keeps Their Buy Rating on Taysha Gene Therapies (TSHA)February 28, 2025 | markets.businessinsider.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Q4 2024 Earnings Call TranscriptFebruary 28, 2025 | msn.comQ4 2024 Taysha Gene Therapies Inc Earnings CallFebruary 27, 2025 | finance.yahoo.comTaysha Gene Therapies Reports 2024 Financial ResultsFebruary 27, 2025 | tipranks.comTaysha Gene Therapies reports FY24 EPS (36c) vs (96c) last yearFebruary 26, 2025 | markets.businessinsider.comTaysha Gene Therapies, Inc. (TSHA) Q4 2024 Earnings Call TranscriptFebruary 26, 2025 | seekingalpha.comTaysha Gene Therapies, Inc. (TSHA) Reports Q4 Loss, Tops Revenue EstimatesFebruary 26, 2025 | zacks.comTaysha Gene Therapies Reports Full-Year 2024 Financial Results and Provides Corporate UpdateFebruary 26, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBMRA, TRDA, ARCT, and TSHA Company DescriptionsArcturus Therapeutics NASDAQ:ARCT$12.91 +0.02 (+0.16%) Closing price 04:00 PM EasternExtended Trading$12.90 -0.01 (-0.04%) As of 05:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.Biomerica NASDAQ:BMRA$3.88 +0.12 (+3.19%) Closing price 04:00 PM EasternExtended Trading$3.84 -0.04 (-1.03%) As of 07:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.Entrada Therapeutics NASDAQ:TRDA$8.84 -0.12 (-1.34%) Closing price 04:00 PM EasternExtended Trading$8.85 +0.01 (+0.11%) As of 04:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.Taysha Gene Therapies NASDAQ:TSHA$1.76 -0.06 (-3.30%) Closing price 04:00 PM EasternExtended Trading$1.74 -0.02 (-1.14%) As of 05:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Market Anticipation Builds: Joby Stock Climbs Ahead of Earnings Is Intuitive Surgical a Buy After Volatile Reaction to Earnings? Now Is the Time to Buy ServiceNow—The Rebound Is Real Archer Aviation Gets Analyst Target Upgrade: Time to Load Up? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
